2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis^†

References

• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–96
   PubMed Web of Science ®Google Scholar
• Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, Kurland LT. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79:1817–22
   PubMed Web of Science ®Google Scholar
• Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, Dungu J, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol 2013;161:525–32
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59
   PubMed Web of Science ®Google Scholar
• Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Expert Rev Hematol 2014;7:143–56
   PubMed Web of Science ®Google Scholar
• Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus RM, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014;124:2325–32
   PubMed Web of Science ®Google Scholar
• Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013;121:5124–30
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005;79:319–28
   PubMed Web of Science ®Google Scholar
• Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008–10
   PubMed Web of Science ®Google Scholar
• Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, Gianni D, et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol 2013;108:378
   PubMed Web of Science ®Google Scholar
• Lavatelli F, Imperlini E, Orrù S, Rognoni P, Sarnataro D, Palladini G, Malpasso G, et al. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. Faseb J 2015;29:4614–28
   PubMed Web of Science ®Google Scholar
• McWilliams-Koeppen HP, Foster JS, Hackenbrack N, Ramirez-Alvarado M, Donohoe D, Williams A, Macy S, et al. Light chain amyloid fibrils cause metabolic dysfunction in human cardiomyocytes. PLoS One 2015;10:e0137716
   PubMed Web of Science ®Google Scholar
• Shi J, Guan J, Jiang B, Brenner DA, del Monte F, Ward JE, Connors LH, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA 2010;107:4188–93
   PubMed Web of Science ®Google Scholar
• Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, Falk RH, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594–7
   PubMed Web of Science ®Google Scholar
• Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, Macy S, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One 2012;7:e52686
   PubMed Web of Science ®Google Scholar
• Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, Fonseca R, et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 2008;112:1931–41
   PubMed Web of Science ®Google Scholar
• Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962;10:355–64
   Web of Science ®Google Scholar
• Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR III, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957–9
   PubMed Web of Science ®Google Scholar
• Rodriguez FJ, Gamez JD, Vrana JA, Theis JD, Giannini C, Scheithauer BW, Parisi JE, et al. Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest 2008;88:1024–37
   PubMed Web of Science ®Google Scholar
• Cohen AS, Calkins E. The isolation of amyloid fibrils and a study of the effect of collagenase and hyaluronidase. J Cell Biol 1964;21:481–6
   PubMed Web of Science ®Google Scholar
• Dapson RW. Macromolecular changes caused by formalin fixation and antigen retrieval. Biotech Histochem 2007;82:133–40
   PubMed Web of Science ®Google Scholar
• Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component. A critical review. Amyloid 1997;4:274–95
   Web of Science ®Google Scholar
• Mollee P, Renaut P, Boros S, Loo D, Hill M. Diagnosis of amyloidosis subtype by laser-capture microdissection (LCM) and tandem mass spectrometry (MS/MS) proteomic analysis. Blood 2013;122:5295
   Web of Science ®Google Scholar
• Blancas-Mejia LM, Ramirez-Alvarado M. Recruitment of light chains by homologous and heterologous fibrils shows distinctive kinetic and conformational specificity. Biochemistry 2016;55:2967–78
   PubMed Web of Science ®Google Scholar
• Oskarsson ME, Paulsson JF, Schultz SW, Ingelsson M, Westermark P, Westermark GT. In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am J Pathol 2015;185:834–46
   PubMed Web of Science ®Google Scholar
• Morales R, Moreno-Gonzalez I, Soto C. Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathogens 2013;9:e1003537
   PubMed Web of Science ®Google Scholar
• Gertz MA, Landau H, Comenzo RL, Seldin DC, Weiss B, Zonder J, Merlini G, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 2016;34:1097–103
   PubMed Web of Science ®Google Scholar
• Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 2015;373:1106–14
   PubMed Web of Science ®Google Scholar
• Langer A, Miao S, Mapara M, Radhakrishnan J, Maurer MS, Raza S, Mears JG, et al. Results of phase I study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Presented at: 57th American Society of Hematology Annual Meeting; December 5-8, 2015; Orlando, Florida. Abstract 188
   Google Scholar